PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15006618-5	2004	When cultured oral SCC cells were incubated with BPA or BSH for 2 h and then exposed to thermal neutrons, the proportion of survival cells that were capable of forming cell colonies decreased exponentially, depending on (10)B concentration.	4-boronophenylalanine	49-52	serpin family B member 3	Homo sapiens	19-22
25585615-5	2015	The results revealed that the antithrombin activity of the boronophenylalanine-modified hirudin to human thrombin was more enhanced than that of rHirudin.	4-boronophenylalanine	59-78	serpin family C member 1	Homo sapiens	30-42
25585615-5	2015	The results revealed that the antithrombin activity of the boronophenylalanine-modified hirudin to human thrombin was more enhanced than that of rHirudin.	4-boronophenylalanine	59-78	coagulation factor II, thrombin	Homo sapiens	34-42
25580517-0	2015	Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.	4-boronophenylalanine	0-19	solute carrier family 1 member 5	Homo sapiens	97-101
25580517-0	2015	Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.	4-boronophenylalanine	0-19	solute carrier family 7 member 5	Homo sapiens	105-109
25580517-0	2015	Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.	4-boronophenylalanine	0-19	linker for activation of T cells family member 2	Homo sapiens	114-118
25580517-7	2015	Among aromatic amino acid transporters, ATB(0,+), LAT1 and LAT2 were found to transport BPA with Km values of 137.4 +- 11.7, 20.3 +- 0.8 and 88.3 +- 5.6 muM, respectively.	4-boronophenylalanine	88-91	solute carrier family 7 member 5	Homo sapiens	50-54
25580517-7	2015	Among aromatic amino acid transporters, ATB(0,+), LAT1 and LAT2 were found to transport BPA with Km values of 137.4 +- 11.7, 20.3 +- 0.8 and 88.3 +- 5.6 muM, respectively.	4-boronophenylalanine	88-91	linker for activation of T cells family member 2	Homo sapiens	59-63
25580517-8	2015	Uptake experiments in cancer cell lines revealed that the LAT1 protein amount was the major determinant of BPA uptake at 100 muM, whereas the contribution of ATB(0,+) became significant at 1000 muM, accounting for 20-25% of the total BPA uptake in MCF-7 breast cancer cells.	4-boronophenylalanine	107-110	solute carrier family 7 member 5	Homo sapiens	58-62
25580517-9	2015	ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo.	4-boronophenylalanine	34-37	solute carrier family 7 member 5	Homo sapiens	10-14
25580517-9	2015	ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo.	4-boronophenylalanine	34-37	linker for activation of T cells family member 2	Homo sapiens	19-23
25580517-9	2015	ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo.	4-boronophenylalanine	142-145	solute carrier family 7 member 5	Homo sapiens	10-14
25580517-9	2015	ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo.	4-boronophenylalanine	142-145	linker for activation of T cells family member 2	Homo sapiens	19-23
25580517-10	2015	The high and low affinities of LAT1 and ATB(0,+), respectively, differentiate their roles in BPA uptake.	4-boronophenylalanine	93-96	solute carrier family 7 member 5	Homo sapiens	31-35
25580517-11	2015	ATB(0,+), as well as LAT1, could contribute significantly to the tumor accumulation of BPA at clinical dose.	4-boronophenylalanine	87-90	solute carrier family 7 member 5	Homo sapiens	21-25
21367608-1	2011	The system L-amino acid transporter (LAT1) imports p-boronophenylalanine (BPA) mainly into proliferating cells.	4-boronophenylalanine	51-72	solute carrier family 7 member 5	Homo sapiens	37-41
21367608-1	2011	The system L-amino acid transporter (LAT1) imports p-boronophenylalanine (BPA) mainly into proliferating cells.	4-boronophenylalanine	74-77	solute carrier family 7 member 5	Homo sapiens	37-41
21367608-2	2011	This study investigates in three tumor entities whether the proportion of tumor cells expressing LAT1 and/or Ki67 correlates with BPA uptake.	4-boronophenylalanine	130-133	solute carrier family 7 member 5	Homo sapiens	97-101
19244126-1	2009	The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy.	4-boronophenylalanine	54-75	solute carrier family 7 member 5	Homo sapiens	11-37
19244126-1	2009	The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy.	4-boronophenylalanine	54-75	solute carrier family 7 member 5	Homo sapiens	39-44
19244126-1	2009	The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy.	4-boronophenylalanine	77-80	solute carrier family 7 member 5	Homo sapiens	11-37
19244126-1	2009	The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy.	4-boronophenylalanine	77-80	solute carrier family 7 member 5	Homo sapiens	39-44
19244126-1	2009	The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy.	4-boronophenylalanine	143-146	solute carrier family 7 member 5	Homo sapiens	11-37
19244126-1	2009	The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy.	4-boronophenylalanine	143-146	solute carrier family 7 member 5	Homo sapiens	39-44
19244126-8	2009	These LAT-1 data indicate that BPA-based boron neutron capture therapy might affect up to 70% of tumor cells, representing a three times higher proportion of tumor cells than their cell cycle status might suggest.	4-boronophenylalanine	31-34	solute carrier family 7 member 5	Homo sapiens	6-11
17997305-1	2007	BACKGROUND: Alix/Bro1p family proteins have recently been identified as important components of multivesicular endosomes (MVEs) and are involved in the sorting of endocytosed integral membrane proteins, interacting with components of the ESCRT complex, the unconventional phospholipid LBPA, and other known endocytosis regulators.	4-boronophenylalanine	285-289	programmed cell death 6 interacting protein	Homo sapiens	12-16
17997305-1	2007	BACKGROUND: Alix/Bro1p family proteins have recently been identified as important components of multivesicular endosomes (MVEs) and are involved in the sorting of endocytosed integral membrane proteins, interacting with components of the ESCRT complex, the unconventional phospholipid LBPA, and other known endocytosis regulators.	4-boronophenylalanine	285-289	Core-binding factor subunit beta homolog bro-1	Caenorhabditis elegans	17-22
17967301-7	2007	The determination of apoptosis in tumor samples by measurements of caspase-3 activity showed an increase in the BNCT (BPA + NA) group at 24 h (p < 0.05 vs. controls) and after the first week after irradiation in the three BNCT groups.	4-boronophenylalanine	118-121	caspase 3	Mus musculus	67-76
17317838-17	2007	Taken together, these data convincingly show the therapeutic efficacy of molecular targeting of EGFR using a boronated mAb either alone or in combination with BPA and provide a platform for the future development of combinations of high and low molecular weight delivery agents for BNCT of brain tumors.	4-boronophenylalanine	159-162	epidermal growth factor receptor	Rattus norvegicus	96-100
15006618-8	2004	These results indicate that BPA is more selectively incorporated into human oral SCC as compared with normal oral tissues, and that both extra- and intra-cellular BPA contribute to the cell-killing effect of BNCT.	4-boronophenylalanine	28-31	serpin family B member 3	Homo sapiens	81-84
15006618-9	2004	BPA may be a useful boron carrier for BNCT in the treatment of advanced oral SCC.	4-boronophenylalanine	0-3	serpin family B member 3	Homo sapiens	77-80
12036929-2	2002	The purpose of the present study was to determine the efficacy of boronated epidermal growth factor (EGF) either alone or in combination with boronophenylalanine (BPA) as delivery agents for an epidermal growth factor receptor (EGFR) -positive glioma, designated F98(EGFR).	4-boronophenylalanine	142-161	epidermal growth factor receptor	Rattus norvegicus	194-226
12036929-2	2002	The purpose of the present study was to determine the efficacy of boronated epidermal growth factor (EGF) either alone or in combination with boronophenylalanine (BPA) as delivery agents for an epidermal growth factor receptor (EGFR) -positive glioma, designated F98(EGFR).	4-boronophenylalanine	142-161	epidermal growth factor receptor	Rattus norvegicus	228-232
12036929-2	2002	The purpose of the present study was to determine the efficacy of boronated epidermal growth factor (EGF) either alone or in combination with boronophenylalanine (BPA) as delivery agents for an epidermal growth factor receptor (EGFR) -positive glioma, designated F98(EGFR).	4-boronophenylalanine	163-166	epidermal growth factor receptor	Rattus norvegicus	194-226
34390745-11	2022	Due to the cancer-specific nature, LAT1 can also be used for cancer-specific delivery of anti-tumor agents such as l-para-boronophenylalanine used for boron neutron capture therapy and alpha-emitting nuclide-labeled LAT1 substrates developed for nuclear medicine treatment.	4-boronophenylalanine	115-141	solute carrier family 7 member 5	Homo sapiens	35-39
10890385-0	2000	Selective uptake of para-boronophenylalanine increases in amelanotic melanoma cells transfected by the tyrosinase gene.	4-boronophenylalanine	20-44	tyrosinase	Mus musculus	103-113
10890385-1	2000	To investigate the mechanism of uptake of para-boronophenylalanine (p-BPA), a capture agent for boron neutron capture therapy (BNCT) of melanoma and brain tumour, into melanoma cells, we studied the relationship between melanin synthesis and the concentration of boron using tyrosinase-deficient mouse amelanotic melanoma cells (A1059) and melanotic melanoma cells (TA1059).	4-boronophenylalanine	42-66	tyrosinase	Mus musculus	275-285
10890385-1	2000	To investigate the mechanism of uptake of para-boronophenylalanine (p-BPA), a capture agent for boron neutron capture therapy (BNCT) of melanoma and brain tumour, into melanoma cells, we studied the relationship between melanin synthesis and the concentration of boron using tyrosinase-deficient mouse amelanotic melanoma cells (A1059) and melanotic melanoma cells (TA1059).	4-boronophenylalanine	68-73	tyrosinase	Mus musculus	275-285
33086625-9	2020	Analyses of in vivo orthotopic tumor also indicated that 100% of SOX2+ or Nestin+ GSLCs were BPA+, whereas only 36.9% of glial fibrillary acidic protein (GFAP)+ DCs were BPA+.	4-boronophenylalanine	93-97	SRY-box transcription factor 2	Homo sapiens	65-69
33956158-1	2021	In this study, we examined whether the cancer cell-killing effects of boron neutron capture therapy (BNCT) are enhanced by manipulating the expression levels of l-type amino acid transporter 1 (LAT1) of human cancer cells, which transports boronophenylalanine into cells.	4-boronophenylalanine	240-259	solute carrier family 7 member 5	Homo sapiens	161-192
33956158-1	2021	In this study, we examined whether the cancer cell-killing effects of boron neutron capture therapy (BNCT) are enhanced by manipulating the expression levels of l-type amino acid transporter 1 (LAT1) of human cancer cells, which transports boronophenylalanine into cells.	4-boronophenylalanine	240-259	solute carrier family 7 member 5	Homo sapiens	194-198
33086625-9	2020	Analyses of in vivo orthotopic tumor also indicated that 100% of SOX2+ or Nestin+ GSLCs were BPA+, whereas only 36.9% of glial fibrillary acidic protein (GFAP)+ DCs were BPA+.	4-boronophenylalanine	93-97	nestin	Homo sapiens	74-80
33076401-6	2020	The system of models developed in this work is potentially useful as an aid for the optimization and individualization of BNCT for HER-2-positive cancers, as well as other cancers, that can be targeted with mAb or a conventional BPA compound.	4-boronophenylalanine	229-232	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-136
32554123-5	2020	These results suggested the relation between LAT-1 expression and boronophenylalanine concentration in vitro.	4-boronophenylalanine	66-85	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	45-50
32010792-1	2020	In the current clinical boron neutron capture therapy (BNCT), p-boronophenylalanine (BPA) has been the most powerful drug owing to its ability to accumulate selectively within cancers through cancer-related amino acid transporters including LAT1.	4-boronophenylalanine	62-83	solute carrier family 7 member 5	Homo sapiens	241-245
32010792-1	2020	In the current clinical boron neutron capture therapy (BNCT), p-boronophenylalanine (BPA) has been the most powerful drug owing to its ability to accumulate selectively within cancers through cancer-related amino acid transporters including LAT1.	4-boronophenylalanine	85-88	solute carrier family 7 member 5	Homo sapiens	241-245
32010792-3	2020	Here, we report that poly(vinyl alcohol) (PVA) can form complexes with BPA through reversible boronate esters in aqueous solution, and the complex termed PVA-BPA can be internalized into cancer cells through LAT1-mediated endocytosis, thereby enhancing cellular uptake and slowing the untoward efflux.	4-boronophenylalanine	158-161	solute carrier family 7 member 5	Homo sapiens	208-212